Momenta Pharmaceuticals Profile

28.00
USD 1.65  6.26%
100%
78%

Acquisition by Matthew Ottmer of 175000 shares of Momenta Pharmaceuticals subject to Rule 16b-3

Momenta Pharmaceuticals insider trading alert for grant of stock option (right to buy) by Matthew Ottmer, Chief Operating Officer, on July 10, 2018. This event was filed by Momenta Pharmaceuticals I with SEC on 2015-12-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Momenta Pharmaceuticals Summary

Momenta Pharmaceuticals (MNTA) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 279 people. Momenta Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.17 B. Momenta Pharmaceuticals conducts business under Healthcare sector and is part of Drugs - Generic industry. This company has 77.36 M outstanding shares of which 5.07 M shares are now shorted by private and institutional investors with about 10.85 trading days to cover. MOMENTA PHARMA currently holds about 323.9 M in cash with (131.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.29.
Check Momenta Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 28.0HorizonTargetOdds Above 28.0
99.80%30 days 28.00 0.20%
Based on normal probability distribution, the odds of Momenta Pharmaceuticals to move above current price in 30 days from now is near 1% (This Momenta Pharmaceuticals probability density function shows the probability of Momenta Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Selected Momenta Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Momenta Pharmaceuticals Against Markets

Current Ratings

Momenta Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
22 
Chance of
Financial Distress (0 to 100%)
40 
Equity ratings for Momenta Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Momenta Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ. It employs 279 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Momenta Pharmaceuticals SEC Filings
Momenta Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameMomenta Pharmaceuticals
CEOCraig WheelerView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS U.S.A
Business Address675 West Kendall Street
ExchangeBATS Exchange
CIK Number0001235010
CUSIP60877T100
SectorHealthcare
IndustryDrugs - Generic
BenchmarkDOW
Websitewww.momentapharma.com
Phone617 491 9700
CurrencyUSD - US Dollar

Momenta Pharmaceuticals Corporate Directors

Bennett Shapiro Independent Director
Georges Gemayel Director, Ph.D
Elizabeth Stoner Independent Director
Please see also Stocks Correlation. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.